Pharmaceuticals company Supriya Lifescience announced Q4FY26 & FY26 results Financial Highlights: Revenue from Operations: The company recorded a revenue of 2,765.28 million for Q4FY26. This represents a growth of 33.95% QoQ (compared to 2,064.40 million in Q3FY26) and a growth of 50.20% YoY (compared to 1,841.09 million in Q4FY25). Annual revenue from operations for FY26 stood at 8,278.75 million, compared to 6,964.85 million in FY25, reflecting a YoY growth of 18.86%. Total Income: Total income for Q4FY26 was 2,800.06 million. This is an increase of 33.94% QoQ (compared to 2,090.51 million in Q3FY26) and 49.67% YoY (compared to 1,870.84 million in Q4FY25). Annual total income for FY26 was 8,393.62 million, compared to 7,063.00 million in FY25, a YoY increase of 18.84%. Profit After Tax (PAT): The profit for the period (PAT) for Q4FY26 was 742.29 million. This represents a growth of 49.43% QoQ (compared to 496.75 million in Q3FY26) and a growth of 47.33% YoY (compared to 503.82 million in Q4FY25). Annual PAT for FY26 was 2,091.20 million, compared to 1,879.58 million in FY25, a YoY increase of 11.26%. Business Highlights: Segment Performance: Segment-wise performance is not applicable as the company does not have any subsidiary, associate, or joint venture company as of March 31, 2026. Dividend: The Board of Directors has recommended a final dividend of Re 1.00 per equity share (50% on the face value of Rs 2/- each) for the financial year ended March 31, 2026, subject to the approval of shareholders at the ensuing Annual General Meeting. Labour Codes Impact: The company has assessed the implications of the New Labour Codes notified by the Government of India and has recognized an incremental cost of 4.58 million towards employee benefits during the year ended March 31, 2026. Accounting Standard: The company has adopted Ind AS 116 "Leases" effective April 01, 2019, using the modified retrospective method. Satish Wagh, Executive Chairman & Whole Time Director, Supriya Lifescience, said: “The strong performance delivered during Q4 FY26 and across the full year reflects steady demand across our key therapeutic segments, healthy traction in regulated markets, and continued operational focus across the business. Improved capacity utilisation, expansion in global markets, and contribution from newly launched products supported growth during the year. During FY26, we continued to strengthen our manufacturing and R&D; infrastructure through capacity enhancement initiatives, strategic land acquisitions, and progress at our Ambernath formulation facility. The commercialisation of the Liquid Anesthetic product, advancement in our finished dosage capabilities, and continued focus on backward integration further strengthened the foundation of our business. With a diversified product portfolio, strong customer relationships across global markets, and ongoing investments in innovation and manufacturing capabilities, the company remains well positioned to drive sustainable long-term growth.” Result PDF